Gland Pharma Limited (the “Company’), one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019 (Source: IQVIA Report), allotted 12,959,089 equity shares to 70 anchor investors and raised Rs 1943.86 crore ahead of the company’s proposed IPO at an upper price band of Rs 1500 per equity shares.
The anchor allocation as follows:
Small Cap World Fund. INC | 6.62% |
Government Of Singapore | 5.32% |
The Nomura Trust And Banking Co. Ltd As The Trustee Of Nomura India Stock Mother Fund | 4.16% |
Goldman Sachs India Limited | 3.31% |
Axis Mutual Fund | 3.02% |
Franklin Templeton Mutual Fund | 3.02% |
SBI Mutual Fund | 3.02% |
Neuberger Berman Emerging Markets Equity Fund | 2.87% |
Aditya Birla Sun Life Mutual Fund | 2.84% |
ICICI Prudential Mutual Fund | 2.84% |
Nippon India Mutual Fund | 2.84% |
Kotak Mutual Fund | 2.46% |
Schroder International Selection Fund Indian Equity | 2.46% |
Morgan Stanley India Investment Fund, Inc. | 2.27% |
HSBC Global Investment Funds – Indian Equity | 2.24% |
Pioneer Investment Fund | 1.89% |
First State Indian Subcontinent Fund | 1.68% |
Fidelity Funds.- India Focus Fund | 1.56% |
Nomura Funds Ireland Public Limited Company- Nomura Funds Ireland – India Equity Fund | 1.51% |
Amundi Funds SBI FM India Equity | 1.51% |
HDFC Life Insurance Company Limited | 1.51% |
Universities Superannuation Scheme Limited (Ussl) As Trustee Of Universities Superannuation Scheme | 1.51% |
Pictet – Indian Equities | 1.51% |
Mirae Mutual Fund | 1.39% |
The Scottish Oriental Smaller Companies Trust Plc | 1.34% |
Fidelity Funds – Asian Special Situations Fund | 1.33% |
Canara Robeco Mutual Fund | 1.32% |
Edelweiss Mutual Fund | 1.32% |
HSBC Mutual Fund | 1.32% |
Invesco Mutual Fund | 1.32% |
L&T Mutual Fund | 1.32% |
Sundaram Mutual Fund | 1.32% |
UTI Mutual Fund | 1.32% |
Monetary Authority Of Singapore | 1.30% |
Investec Global Strategy Fund – Asian Equity Fund | 1.17% |
Jupiter India Fund | 1.14% |
Investec Global Strategy Fund – Emerging Markets Equity Fund | 1.04% |
Ashoka India Opportunities Fund | 0.95% |
Baroda Mutual Fund | 0.95% |
IDFC Mutual Fund | 0.95% |
Worldwide Healthcare Trust Plc | 0.95% |
Neuberger Berman Investment Funds Plc/Neuberger Berman Emerging Market Equity Fund | 0.91% |
Lion Global Asia Pacific Fund | 0.76% |
PGIM India Mutual Fund | 0.76% |
Cohesion MK Best Ideas Sub-Trust | 0.75% |
Elara India Opportunities Fund | 0.75% |
Ghisallo Master Fund LP | 0.75% |
Government Pension Fund Global | 0.75% |
Lockheed Martin Corporation Master Retirement Trust | 0.75% |
Max Life Insurance Company Limited | 0.75% |
SBI Life Insurance Company Limited | 0.75% |
Segantii India Mauritius | 0.75% |
Stichting Depositary APG Emerging Markets Equity Pool | 0.75% |
HSBC Indian Equity Mother Fund | 0.60% |
Fidelity Funds – Asian Smaller Companies Pool | 0.59% |
Morgan Stanley Investment Funds Indian Equity Fund | 0.57% |
Greater India Portfolio | 0.47% |
Investec Global Strategy Fund – Asia Pacific Equity Opportunities Fund | 0.44% |
Fidelity Funds – Asian Equity Pool | 0.40% |
Avendus Absolute Return Fund | 0.38% |
Bharti AXA Life Insurance Company Ltd | 0.38% |
BNP Paribas Arbitrage ODI | 0.38% |
Klay Funds Limited | 0.38% |
Moon Capital Trading Pte. Ltd. | 0.38% |
Rochdale Emerging Markets (Mauritius) | 0.38% |
Tata AIA Life Insurance Company Limited | 0.38% |
Edelweiss Alternate Investment Opportunities Trust – Edelweiss Crossover Opportunities Fund – Series II | 0.38% |
Malabar Select Fund | 0.38% |
Malabar India Fund Limited | 0.37% |
Fidelity Asian Values PLC | 0.28% |
The Initial Public offering comprises of a fresh issue aggregating up to Rs. 12,500 million (the “Fresh Issue”) and an offer for sale of up to 34,863,635 Equity Shares, including up to 19,368,686 Equity Shares by Fosun Pharma Industrial PTE. Ltd (“Promoter Selling Shareholder”) and up to 10,047,435 Equity Shares by Gland Celsus Bio Chemicals Private Limited, up to 3,573,014 Equity Shares by Empower Discretionary Trust, and up to 1,874,500 Equity Shares by Nilay Discretionary Trust (collectively, the “Other Selling Shareholders” and collectively with the Promoter Selling Shareholder are referred to as the “Selling Shareholders”, and such Equity Shares, the “Offered Shares”).
Bids can be made for a minimum of 10 Equity Shares and in multiples of 10 Equity Shares thereafter.
The Equity Shares offered pursuant to the Offer are proposed to be listed on BSE Limited and National Stock Exchange of India Limited (“NSE”). For the purpose of the Offer, NSE is the designated stock exchange.
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, Haitong Securities India Private Limited and Nomura Financial Advisory and Securities
(India) Private Limited are the Book Running Lead Managers to the Offer (“BRLMs”).